PTEN and neoplasm: Consistently, activating mutations in PIK3CA are identified in 11% of LGSOC tumours [44], and inactivating PTEN mutations occur in 20% of cases [45], suggesting that PI3K pathway inhibition can become a central target in LGSOCs.